文献速递心脑血管急症

心电图筛查心房颤动:美国预防服务工作组证据报告与系统综述

Screening for Atrial Fibrillation With Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2018-01-01
一句话结论心电图筛查可发现更多未诊断的房颤,但未证明优于脉搏触诊筛查;治疗可降低卒中与全因死亡风险但增加出血风险。

本系统综述纳入17项研究(n=135300),旨在为美国预防服务工作组评估65岁及以上无症状成人非瓣膜性房颤的心电图筛查及卒中预防治疗证据。结果显示,系统心电图筛查较不筛查可发现更多新发房颤(12个月内绝对增加从0.6%至2.8%),但较脉搏触诊筛查未发现更多病例。华法林治疗(平均1.5年)与缺血性卒中风险降低(RR 0.32)和全因死亡风险降低(RR 0.68)相关,但出血风险增加。未评估筛查检出后治疗是否较常规照护或症状出现后治疗带来更好健康结局。

要点

  • 系统心电图筛查较不筛查在12个月内新发房颤绝对增加从0.6%(95%CI 0.1%-0.9%)至2.8%(95%CI 0.9%-4.7%)(2项RCT,n=15803)。
  • 系统心电图筛查与脉搏触诊筛查相比未发现更多房颤病例(2项RCT,n=17803)。
  • 华法林(平均1.5年)与缺血性卒中风险降低相关(RR 0.32,95%CI 0.20-0.51)及全因死亡风险降低相关(RR 0.68,95%CI 0.50-0.93),但出血风险增加(5项试验,n=2415)。
  • 治疗试验参与者非筛查检出,多数为长期持续性房颤。
  • 尚无研究评估筛查检出后治疗是否较常规照护或症状出现后治疗改善健康结局。

适用人群与场景

  • 65岁及以上无症状成人,无心血管疾病史(排除有心血管疾病史者)。

研究设计与关键结果

  • 系统综述纳入17项研究,总样本量135300例。
  • 无研究评估筛查与不筛查对健康结局的影响。
  • 系统心电图筛查较不筛查发现更多新发房颤:12个月内绝对增加从0.6%(95%CI 0.1%-0.9%)至2.8%(95%CI 0.9%-4.7%)(2项RCT,n=15803)。
  • 系统心电图筛查与脉搏触诊筛查相比未发现更多房颤病例(2项RCT,n=17803)。
  • 无合格研究比较筛查与不筛查的潜在危害。
  • 华法林(平均1.5年)与缺血性卒中风险降低相关(RR 0.32,95%CI 0.20-0.51)及全因死亡风险降低相关(RR 0.68,95%CI 0.50-0.93),出血风险增加(5项试验,n=2415)。
  • 网络Meta分析报告NOACs与卒中及系统性栓塞复合结局风险显著降低相关(校正OR较安慰剂或对照范围为0.32-0.44);出血风险增加(校正OR 1.4-2.2),但置信区间宽且组间差异无统计学显著。

证据类型、等级与局限

  • 证据类型:系统综述(针对美国预防服务工作组)。
  • 治疗试验参与者非筛查检出,多数为长期持续性房颤。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 心电图筛查可发现未诊断的房颤,但未证明较脉搏触诊筛查发现更多病例。
  • 治疗房颤可降低卒中及全因死亡风险并增加出血风险,但筛查检出后治疗是否较常规照护或症状出现后治疗改善健康结局尚未评估。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Atrial fibrillation is the most common arrhythmia and increases the risk of stroke.

OBJECTIVE: To review the evidence on screening for nonvalvular atrial fibrillation with electrocardiography (ECG) and stroke prevention treatment in asymptomatic adults 65 years or older to inform the US Preventive Services Task Force.

DATA SOURCES: MEDLINE, Cochrane Library, and trial registries through May 2017; references; experts; literature surveillance through June 6, 2018.

STUDY SELECTION: English-language randomized clinical trials (RCTs), prospective cohort studies evaluating detection rates of atrial fibrillation or harms of screening, and systematic reviews evaluating stroke prevention treatment. Eligible treatment studies compared warfarin, aspirin, or novel oral anticoagulants (NOACs) with placebo or no treatment. Studies were excluded that focused on persons with a history of cardiovascular disease.

DATA EXTRACTION AND SYNTHESIS: Dual review of abstracts, full-text articles, and study quality. When at least 3 similar studies were available, random-effects meta-analyses were conducted.

MAIN OUTCOMES AND MEASURES: Detection of previously undiagnosed atrial fibrillation, mortality, stroke, stroke-related morbidity, and harms.

RESULTS: Seventeen studies were included (n = 135 300). No studies evaluated screening compared with no screening and focused on health outcomes. Systematic screening with ECG identified more new cases of atrial fibrillation than no screening (absolute increase, from 0.6% [95% CI, 0.1%-0.9%] to 2.8% [95% CI, 0.9%-4.7%] over 12 months; 2 RCTs, n = 15 803), but a systematic approach using ECG did not detect more cases than an approach using pulse palpation (2 RCTs, n = 17 803). For potential harms, no eligible studies compared screening with no screening. Warfarin (mean, 1.5 years) was associated with a reduced risk of ischemic stroke (relative risk [RR], 0.32 [95% CI, 0.20-0.51]) and all-cause mortality (RR, 0.68 [95% CI, 0.50-0.93]) and with increased risk of bleeding (5 trials, n = 2415). Participants in treatment trials were not screen detected, and most had long-standing persistent atrial fibrillation. A network meta-analysis reported that NOACs were associated with a significantly lower risk of a composite outcome of stroke and systemic embolism (adjusted odds ratios compared with placebo or control ranged from 0.32-0.44); the risk of bleeding was increased (adjusted odds ratios, 1.4-2.2), but confidence intervals were wide and differences between groups were not statistically significant.

CONCLUSIONS AND RELEVANCE: Although screening with ECG can detect previously unknown cases of atrial fibrillation, it has not been shown to detect more cases than screening focused on pulse palpation. Treatments for atrial fibrillation reduce the risk of stroke and all-cause mortality and increase the risk of bleeding, but trials have not assessed whether treatment of screen-detected asymptomatic older adults results in better health outcomes than treatment after detection by usual care or after symptoms develop.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Jonas DE, Kahwati LC, Yun JDY, et al. Screening for Atrial Fibrillation With Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018. PMID: 30088015. doi:10.1001/jama.2018.4190

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。